ArteraAI Secures Additional $20M Funding to Globalize AI-Driven Cancer Personalization Tests.
ArteraAI is at the forefront of integrating AI in precision medicine to revolutionize cancer treatment.
Company Name: ArteraAI
Location: San Francisco, CA
Sector: Precision Medicine, Artificial Intelligence in Oncology
Funding Details: Raised an additional $20M, with participation from Prosperity7 Ventures, EDBI, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, and Trium Ventures. Notable individual investors include Navin Chaddha, Rajiv Khemani (AISpace VC), and Andrew & Elliott Tan (A&E Investment LLC).
Purpose of Investment: For international expansion and commercial growth of the company and its ArteraAI Prostate Test.
Leadership: CEO Andre Esteva
Product: ArteraAI Prostate Test, a multimodal artificial intelligence (MMAI)-based biomarker test that personalizes cancer therapy by predicting therapy benefits and prognostic outcomes for patients with localized prostate cancer.
About Company: ArteraAI is at the forefront of integrating AI in precision medicine to revolutionize cancer treatment. By developing predictive and prognostic tests, the company aims to personalize therapy for cancer patients, starting with prostate cancer.
Innovation and Impact:
- Multimodal AI (MMAI) Approach: Combines digital biopsy images and clinical data to predict therapy outcomes.
- Personalized Cancer Therapy: Enhances treatment decisions for localized prostate cancer patients.
- CLIA-certified Laboratory: Ensures clinical availability and reliability of the ArteraAI Prostate Test.
Strategic Goals: This funding will accelerate ArteraAI's global presence and the adoption of its AI-enabled tests in clinical settings, promising a new era in cancer treatment personalization.